Alteplase
Depends on presentation or useFull monograph review pending
Historical dilution reference. Verify the preparation against the label for the product in hand.
Original GlobalRPh article: Alteplase (opens in a new tab)Original source URL: https://globalrph.com/dilution/alteplase/ Retrieved 2026-11-04
Historical source details
Original publication date: unavailable in the retrieved article.
Source location and file checksums
- Original source URL
- https://globalrph.com/dilution/alteplase/ (opens in a new tab)
- Source date
- Not established in the retrieved source
- Retrieved
- 2026-11-04T19:45:43.196726+00:00
- Source location
- div.post-content
- Packaged content SHA-256
- 27d28687e4dc26a444883577951da999717023ec708424cd3d6beb94cb0aebbd
- Original response SHA-256
- 633be7627fb8220f2cd2d923708f186acdb39d7789100199ace65c20937107c3
- Source body SHA-256
- e125b055de2aed4ad1a1cb49e15ad702dcda4e1f7712e348843d7d5b2b48a2d4
Alteplase - (ACTIVASE, TPA) |
||||||||||||||||||||||||
| The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer | ||||||||||||||||||||||||
Usual Diluents |
||||||||||||||||||||||||
| NS, D5W | ||||||||||||||||||||||||
Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate] |
||||||||||||||||||||||||
| Note: Sterile water without preservative [50 mg vial] [50 ml - SW] [UD] [100 mg vial] [100 ml - SW ] [UD] Peripheral arterial occlusive disease: Continuous infusion of alteplase: 0.5 to 2 mg/hr x 6 to 72 hours depending on location. Preparation: Dilute alteplase with sterile water as above, then further dilute with NS to produce one of the following concentrations below: Concentration (0.1 mg/ml) Concentration (0.2 mg/ml) Alternatives: Concentration (0.05 mg/ml) |
||||||||||||||||||||||||
Stability / Miscellaneous |
||||||||||||||||||||||||
EXP: 8 hours (RT). Prepare just before use. Results in concentration of 1 mg/ml. May be infused at this concentration or may dilute further with equal volume of normal saline or D5W (0.5 mg/ml).
Dosing: Pulmonary embolism: 100 mg over 2 hours.
Intracatheter: Cathflo® Activase® (Alteplase) is for instillation into the dysfunctional catheter at a concentration of 1 mg/mL. DOSAGE AND ADMINISTRATION Instructions for Administration Instillation of Solution into the Catheter Inspect the product prior to administration for foreign matter and discoloration. Withdraw 2 mL (2 mg) of solution from the reconstituted vial. Instill the appropriate dose of Cathflo Activase (see DOSAGE AND ADMINISTRATION) into the occluded catheter. After 30 minutes of dwell time, assess catheter function by attempting to aspirate blood. If the catheter is functional, go to Step 7. If the catheter is not functional, go to Step 5. After 120 minutes of dwell time, assess catheter function by attempting to aspirate blood and catheter contents. If the catheter is functional, go to Step 7. If the catheter is not functional, go to Step 6. If catheter function is not restored after one dose of Cathflo Activase, a second dose of equal amount may be instilled. Repeat the procedure beginning with Step 1 under Preparation of Solution. If catheter function has been restored, aspirate 4-5 mL of blood in patients >/=10 kg or 3 mL in patients <10 kg to remove Cathflo Activase and residual clot, and gently irrigate the catheter with 0.9% Sodium Chloride Injection, USP. Any unused solution should be discarded. Stability and Storage Store lyophilized Cathflo Activase at refrigerated temperature (2-8°C/36-46°F). Do not use beyond the expiration date on the vial. Protect the lyophilized material during extended storage from excessive exposure to light. HOW SUPPLIED Cathflo Activase (Alteplase) for injection is supplied as a sterile, lyophilized powder in 2 mg vials. Each Cathflo®Activase® carton contains one 2 mg vial of Cathflo® Activase® (Alteplase): NDC 50242-041-64. Intra-arterial: Acute peripheral arterial occlusive disease (unlabeled use): 0.02-0.1 mg/kg/hour for up to 36 hours Advisory Panel to the Society for Cardiovascular and Interventional Radiology on Thrombolytic Therapy recommendation: </=2 mg/hour and subtherapeutic heparin (aPTT <1.5 times baseline) Additional info |
||||||||||||||||||||||||
U.S. label preparation
Activase · Depends on presentation or use
- Preparation
- Systemic Activase only. Reconstitute the 50 mg or 100 mg vial with the matching supplied volume of preservative-free sterile water (50 or 100 mL) to make 1 mg/mL. The 100 mg kit uses the supplied transfer device. Cathflo 2 mg catheter clearance has separate instructions.
- Administration and handling
- Give at 1 mg/mL or dilute immediately before administration with an equal volume of 0.9% sodium chloride or 5% dextrose to 0.5 mg/mL. Use a PVC bag or glass vial. Select the indication-specific bolus and infusion regimen.
Product and source details
Genentech, Inc. · BLA103172
Product NDC: 50242-044, 50242-085
SPL effective 2026-01-20 | SPL version 15. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.
Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)